Key Highlights

  • Acute therapies, growing at a high single-digit pace, helped lift net Revenue 4.1% to USD 1.49 billion from USD 1.44 billion.
  • Profit reached USD 57.4 million, equal to USD 0.38 a diluted share, a 10.8% increase on the USD 0.32 per share (USD 51.8 million) earned last year.
  • Operating income reached USD 89.2 million, up from USD 84.5 million, while merger-related Transaction Costs were embedded in SG&A.
  • Shareholders would receive USD 32.05 in cash per share under an October 5, 2026 Merger agreement, and management expects closing in the first half of calendar 2027.

Acute Therapies Power a Modest Top-Line Gain

Option Care Health (NASDAQ:OPCH) posted quarterly figures on November 4, 2026. Its core Business is home and alternate site infusion. Net revenue came in at USD 1,493.5 million versus USD 1,435.0 million, and Gross Profit increased 4.4% to USD 285.0 million, lifting gross Margin to 19.1% from 19.0%. Management credited growth in higher-margin therapies and continued operating efficiencies. Nine-month revenue reached USD 4.29 billion, up 2.5%, while nine-month Net Income was USD 156.7 million, or USD 1.02 per diluted share, against USD 149.1 million, or USD 0.91.

Merger Costs and a Tax Swing Shape the Profit Line

Selling, general and administrative expenses climbed 3.2% to USD 177.6 million, largely due to merger transaction costs. Lower borrowing costs brought interest expense down to USD 12.9 million, compared with USD 14.1 million a year earlier. Other, net swung from a USD 3.6 million expense to a USD 1.0 million credit, a shift the filing mostly ties to a USD 4.7 million Debt extinguishment loss booked in the third quarter of 2025 that did not recur. Income tax expense increased 25.2% to USD 21.5 million. Despite spending USD 167.5 million on share repurchases during the first nine months, cash and equivalents climbed to USD 299.1 million from USD 232.6 million at December 31, 2025.

Deal Terms, Closing Conditions and a Buyback Freeze

Once completed, the company would go private under an investor group that brings together affiliates of Clayton, Dubilier & Rice and McKesson, and its shares would stop trading publicly. Completion hinges on a majority stockholder vote, antitrust clearance under the Hart-Scott-Rodino Act and healthcare regulatory approvals. Either party may terminate the agreement if closing has not happened by October 5, 2027, and in certain cases the company would owe a termination fee near USD 145.96 million. Dividends and repurchases need the buyer's consent. This year the company retired 7.9 million shares for USD 167.5 million, none of them in the third quarter, with an average price of USD 21.26 a share, which places the USD 32.05 offer roughly 51% higher (calculated).

Where Things Stand

The results look steady rather than transformative, and the pending deal now frames them. The company's revenue rose 4.1%, its net income 10.8% and diluted EPS reached USD 0.38, even with merger costs in the mix. Because the USD 32.05 cash price is fixed, better operating results would not add to what holders receive. Because the cash price is fixed, the trading value of the shares is more closely tied to deal completion than to quarterly operating results. The filing lists regulatory approvals, a stockholder vote, litigation challenging the transaction and operating disruption as risks. Watch items now include the stockholder meeting, regulatory sign-offs and the first-half 2027 closing window.